Overcoming EGFR mutation non-small cell lung cancer resistance First three total HER3 targeted ADC clinical results were positive.

Lung cancer is one of the most common cancers in the world and the leading cause of cancer death worldwide, and most lung cancers are diagnosed with advanced or metastasis cancers.
about 15%-50% of patients with non-small cell lung cancer carry EGFR mutations, of which about 83% express HER3 protein, which may be associated with increased metastasis, reduced survival and resistance to standard treatment.
The Patritumab deruxtecan is designed using the proprietary DXd ADC technology of the first three companies, connecting anti-HER3 antibodies to topological isomerase inhibitors through a tetephite connection.
(U3-1402) introduction (Photo: First Three Commons) The number of median pre-treatments received by patients who participated in the study was 4.
all patients were treated with EGFR TKI, most of whom received osimertinib (86%), 90% received platinum-containing chemotherapy, and 40% received anti-PD-1/PD-L1 antibody therapy.
study, 47 percent of assessable patients had a history of brain metastasis.
they represent a very difficult group of patients.
trial results showed that in 56 patients who could be assessed, patritumab deruxtecan achieved an objective remission rate (ORR) of 25%, one patient achieved complete remission (CR) and 13 patients achieved confirmed partial remission.
and three patients had their partial remission to be confirmed by the data cut-off.
70% in patients with the disease and 6.9 months in the medium remission.
"These initial responses are very encouraging given the lack of approved effective treatments for these patients," said Dr. Helena Yu of Memorial Sloan-Kettering Cancer Center, one of the trial leaders.
" References: . . . Daiichi Sankyo Announces Late-Breaking Phase 1 Dose Data for Patritumab Deruxtecan in Patients with EGFR-Muted NSCLC at ESMO 2020. Retrieved September 18, 2020, from.